Nicolas Villain, MD, PhD, AP-HP Sorbonne University, Pitié-Salpêtrière Hospital, Paris, France, comments on the International Working Group’s updated criteria for diagnosing Alzheimer’s disease (AD). He highlights new evidence that identifies two distinct subgroups with differing risks of progression: those with amyloid positivity and tau negativity and those with amyloid positivity and tau positivity. The International Working Group proposes expanding the definition of pre-symptomatic AD, while maintaining the distinction between asymptomatic individuals at risk and those with actual pre-symptomatic Alzheimer’s disease. This interview took place at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
